Epilepsy Epidiolex denied as not FDA-approved for this use by Cigna?

Cigna's specific coverage criteria for epilepsy epidiolex are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna May Deny Epidiolex as Not FDA-Approved — and Why This Denial Is Factually Incorrect

Epidiolex (cannabidiol) holds FDA approval for specific rare epilepsy syndromes. A "not FDA-approved" denial for Epidiolex almost always results from one of three scenarios: (1) the diagnosis code submitted does not match the FDA-approved indication as recognized in Cigna's system; (2) Cigna's internal drug database has not been updated to reflect a recent label expansion; or (3) the prescribing indication is off-label but supported by recognized medical guidelines. In the first two scenarios, the denial is factually wrong and readily corrected with documentation. In the third, the appeal path focuses on medical guideline support.

## Why This Denial Is Appealable

If Epidiolex is being prescribed for an FDA-approved indication, attaching the FDA-approved prescribing label and a letter from the treating neurologist confirming the matching diagnosis is often sufficient to overturn the denial at the internal appeal stage. If the use is off-label, your appeal will pivot to demonstrating support in established guidelines from relevant professional epilepsy or neurology organizations — a recognized basis for coverage under most plan documents and applicable law.

## Your Federal Appeal Rights

• Internal appeal: ACA §2719 and ERISA §503 entitle you to a full-and-fair internal review. File within the deadline in your denial letter.
• External review: If the internal appeal is denied, you have approximately four months to request independent external review. An IRO with neurology expertise will assess whether the denial is consistent with current FDA regulations and accepted medical practice.
• Expedited review: Request expedited processing if uncontrolled seizures create an immediate safety risk; turnaround is 72 hours.

## Documentation to Gather

1. FDA prescribing information: Print the current FDA-approved label for Epidiolex, highlight the approved indications, and include it as Exhibit A in your appeal package. 2. Diagnosis confirmation matching the label: EEG records, genetic testing, and specialist notes confirming that the patient's diagnosis falls within an FDA-approved indication. 3. Prescriber letter addressing the denial: A letter from the treating neurologist that (a) identifies the FDA-approved indication, (b) confirms the patient's diagnosis matches it, and (c) if off-label use is involved, cites support from the applicable clinical guideline organization. 4. Guideline support (if off-label): Reference to recommendations from the relevant professional organization (e.g., American Epilepsy Society) endorsing the use — without citing specific statistics. 5. Claim and coding review: Verify with the prescriber's office that the ICD-10 diagnosis code submitted on the prior-authorization request correctly reflects the FDA-labeled indication. A coding mismatch is the most common and most easily fixed root cause.

## Criteria-Mapping Structure

Review Cigna's Epidiolex coverage policy from the Cigna policy portal:

| Denial Basis | Rebuttal Document | |---|---| | Not FDA-approved for submitted diagnosis | [FDA label — approved indication + patient diagnosis match] | | Diagnosis code mismatch | [Corrected ICD-10 code from treating neurologist] | | Off-label use not supported | [Guideline reference from treating specialist's letter] |

A single well-organized appeal letter with the FDA label attached resolves the majority of these denials without requiring external review.